|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We studied 86 adult offspring (mean age 40 years), 49 born to glucokinase mothers (exposed to hyperglycaemia in utero) and 37 born to glucokinase fathers (controls).
|
17216282 |
2007 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To assess the association between chronic, mild hyperglycemia and complication prevalence and severity in patients with GCK mutations.
|
24430320 |
2014 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Moreover, an additive effect of GCKR rs1260326(T) and GCK (-30G) alleles conferred lower fasting glycemia (P = 1 x 10(-13)), insulinemia (P = 5 x 10(-6)), and hyperglycemia risk (P = 1 x 10(-6)).
|
18556336 |
2008 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
This nonradioactive SSCP technique may be useful to routinely diagnose glucokinase deficiency, which is an important cause of hyperglycemia among young type II diabetic patients.
|
8168652 |
1994 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In pregnancies where the mother has hyperglycemia due to a GCK mutation, knowing the fetal GCK genotype guides the management of maternal hyperglycemia.
|
22773699 |
2012 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Functional studies of naturally occurring GCK mutations associated with hyperglycaemia provide further insight into the biochemical basis of glucose sensor regulation.
|
17186219 |
2007 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis.
|
10525657 |
1999 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The findings leading to the diagnosis were impaired fasting glucose (IFG) (15/37), symptoms of hyperglycemia (4/37), and a GCK-MODY family history (18/37).
|
28663157 |
2017 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Heterozygous inactivating mutations in the GCK gene cause the familial, mild fasting hyperglycaemia named MODY2.
|
29704611 |
2018 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
MODY due to mutations in the glucokinase gene is a relatively mild form of diabetes with mild fasting hyperglycemia and IGT in the majority.
|
8035658 |
1994 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
GCK-MODY leads to mildly elevated blood glucose typically not requiring therapy.
|
27106716 |
2016 |
|
Hyperglycemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We developed a gene therapy approach to control diabetic hyperglycemia based on co-expression of the insulin and glucokinase genes in skeletal muscle.
|
28626777 |
2017 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The principal objective of the current study is to determine the outcomes and clinical management of hyperglycemia in pregnancies complicated by glucokinase gene (GCK) and hepatocyte nuclear factor (HNF)-1α MODY mutations.
|
25935773 |
2015 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The glucokinase V62M and G72R mutations are naturally occurring and known to associate with hyperglycemia in humans.
|
19187021 |
2009 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in glucokinase/MODY2 result in mild chronic hyperglycaemia due to reduced pancreatic beta-cell responsiveness to glucose as well as decreased net accumulation of hepatic glycogen and increased hepatic gluconeogenesis following meals.
|
9162575 |
1997 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
MODY 2 is characterized by mild asymptomatic fasting hyperglycemia, and rarely requires pharmacological treatment.
|
23295292 |
2012 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Identification and functional analysis of GCK gene mutations in 12 Chinese families with hyperglycemia.
|
30592380 |
2019 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings link defects in hormone-regulated GCK S-nitrosylation to hyperglycemia and support a role for posttranslational regulation of GCK S-nitrosylation as a vital regulatory mechanism for glucose-stimulated insulin secretion.
|
19934346 |
2010 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This novel mutation in the glucokinase gene led to atypical symptomatic exercise-induced hyperglycaemia that was responsive to low dose sulfonylurea with self-reported additional benefit after reduction of carbohydrate intake.
|
24503189 |
2014 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous mutations in glucokinase (GCK) are associated with mild fasting hyperglycemia and gestational diabetes mellitus while homozygous or compound heterozygous GCK mutations result in permanent neonatal diabetes mellitus.
|
21978167 |
2012 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The GCK-MODY was identified by incidental hyperglycemia without glycosuria.
|
31216263 |
2019 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A novel glucokinase deletion (p.Lys32del) and five previously described mutations co-segregate with the phenotype of mild familial hyperglycaemia (MODY2) in Brazilian families.
|
23433541 |
2013 |
|
Hyperglycemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Rare mutations of GCK cause fasting hyperglycemia and alter birth weight.
|
17186458 |
2006 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The most frequently observed combinations of symptoms typical for GCK-MD were mild diabetes and/or fasting hyperglycaemia (98.3%), positive C-peptide at diagnosis (76%) and dominant mode of inheritance (59%).
|
21348868 |
2012 |
|
Hyperglycemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We assessed the contribution of hyperglycemia by comparing insulin sensitivity in control and GCK-MODY and the contribution of hyperinsulinemia by comparing GCK-MODY and type 1 diabetes.
|
31092478 |
2019 |